The 2022 AABB Virtual Meeting will be Nov. 6-7. Attendees can visit the
meeting homepage
for details on accessing the virtual platform.
For Donors & Patients
Give Blood
Why Donate Blood?
About Blood Donation
FAQs About Blood and Blood Donation
Find a DNA Lab
Cord Blood & Other Cell Therapies
Annual Meeting
Go
Schedule
Learn
Exhibit
News
Foundation
Introducing the AABB Foundation
Early-Career Scientific Research Grants Program
Annual Grant Recipients
Annual Scholar Recipients
Award for Innovative Research
Hall of Fame Inductees
Partner with the AABB Foundation
Support the AABB Foundation
AABB Store
All Products
Publications
Education
Donations
Resources
Utility
Login
My Account
Welcome,
User
My Profile
Logout
Search
Membership
Prospective Members
Member Benefits
Join AABB
Current Members
My Account
Renew My Membership
Membership Directory
Committees & Sections
Standards & Accreditation
Standards
About AABB Standards
Standards FAQs
Updated Quality Systems Essentials
Standards Library
Requesting a Variance
Requesting a Standards Clarification
Purchase Standards
Standards Portal
Access Standards
Standards Portal Free Trial
Standards Portal FAQs
Accreditation
Become AABB-Accredited
Blood Collection
Transfusion Services
Biotherapies Services
Relationship (DNA) Testing
AABB Accreditation Process
Accreditation Portal
Accredited Member Tools
Assessor Information
Accredited Facilities
AABB Accredited Blood Banks, Transfusion Services, and Blood Centers
Cellular Therapy Facilities
AABB Accredited Relationship (DNA) Testing Facilities
Commendable Practices
CLIA Corner
Quality
Quality Toolkit
News & Resources
News
AABB Newsfeed
AABB News Magazine
TRANSFUSION Journal
Resources
Transfusion Medicine
Blood Donation FAQs
Iron Management Among Blood Donors
AABB Babesiosis Risk-Based Decision-Making Assessment Report
Highlights of Transfusion Medicine History
Individual Donor Assessment Resources
Biotherapies
Certified Advanced Biotherapies Professional (CABP)
Cellular Therapies Certificate Program
Flow Cytometry Course
Circular of Information for CT Products
CT Subsection Projects
Facts About Cellular Therapies
International Ambassadors
ISBT 128 for Cellular Therapy
Patient Blood Management
Patient Blood Management Toolkit
Patient Blood Management Certification
Hemovigilance
Donor Hemovigilance
Recipient Hemovigilance
Zika Virus Biovigilance Network
West Nile Virus Biovigilance Network
Chagas Biovigilance Network
AABB Surveys and Reports
Contact Us - AABB Hemovigilance
Clinical Practice Resources
Association Bulletins
Circular of Information
Donor History Questionnaires
Blood Donor History Questionnaires
Evaluating Donors for Risk of Ebola Virus Infection
Hematopoietic Progenitor Cell, Apheresis and Marrow Donor History Questionnaire
Hematopoietic Progenitor Cell, Cord Blood Donor History Questionnaire
Billing Guide
Job Board
Education
Calendar of Events
Annual Meeting
Certified Advanced Biotherapies Professional (CABP)
Meetings On-Demand
eCasts
Hot Topic Discussions
Courses
Certificate Programs
Science & Innovation Forums
Publications
Access My Learning Programs
CE/CME Information
AABB Community
Workforce Initiatives
Regulatory & Advocacy
Regulatory Affairs
Regulatory for Blood and Blood Components
Donor Safety, Screening and Testing
Labeling
Whole Blood and Red Blood Cell Components
Plasma Components
Platelet Components
Irradiation
Regulatory Resources
AABB's Regulatory Toolkits for Members
Resources for Transfusion Services
Regulatory Updates and Resources for Blood and Blood Components
Regulatory Analysis
Infectious Diseases
Babesiosis
Chagas Disease
CJD AND vCJD
AABB COVID-19 Resources
Hepatitis
HIV
Human T-Lymphotropic Virus, Types I and II
Malaria
Syphilis
West Nile Virus
Zika Virus
Emerging Infectious Disease Agents
Government Advisory & Regulatory Meetings
Blood Products Advisory Committee
Cellular, Tissue and Gene Therapies Advisory Committee
Public Meetings and Workshops
FDA Liaison Meetings - Blood and Blood Components
Cellular Therapies Meetings and Collaborations
Regulatory for Cellular Therapies
HCT/Ps
Biological Products
Investigational Cellular Therapies
International Competent Authorities
Advocacy
Advocacy Agenda
AABB Statements and Comments to FDA
Blood Sustainability
Patient & Donor Safety
Cellular Therapies & Biotherapies
Coverage & Reimbursement
About AABB
Organization
AABB History
75 Years of AABB
Past Presidents
Governance & Policies
Structure and Governance Overview
Board of Directors
Nominations & Elections
DEIA Action Plan
Disaster Response
Press
Contact Us
AABB Departmental Directory
Directory of National Office Staff
Corporate Services
National Blood Exchange
Consulting Services
Global Services
Corporate Partner Program
Supplier Guide
Media Kit 2023
FDA 510(k) Third-Party Review
Standards-Compliant Products
Cellular Starting Material Qualification
Get Involved
Join AABB
Volunteer
Alliance for a Strong Blood Supply
Awards
AABB Memorial Awards
AABB Foundation Award for Innovative Research
RISE Award
President's Awards
AABB Future Leader Scholarship Awards Program
2022 AABB Award Recipients
List of Past AABB Awards Recipients
AABB Community
Committees & Sections
Home
Regulatory & Advocacy
Regulatory Affairs
Infectious Diseases
Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety
Fact Sheets Created or Updated Post Publication of the TRANSFUSION August 2009 Supplement
Fact Sheets Created or Updated Post Publication of the TRANSFUSION August 2009 Supplement
Regulatory & Advocacy
Regulatory Affairs
Regulatory for Blood and Blood Components
Donor Safety, Screening and Testing
Labeling
Whole Blood and Red Blood Cell Components
Plasma Components
Platelet Components
Irradiation
Regulatory Resources
AABB's Regulatory Toolkits for Members
Resources for Transfusion Services
Regulatory Updates and Resources for Blood and Blood Components
Regulatory Analysis
Infectious Diseases
Babesiosis
Chagas Disease
CJD AND vCJD
AABB COVID-19 Resources
Hepatitis
HIV
Human T-Lymphotropic Virus, Types I and II
Malaria
Syphilis
West Nile Virus
Zika Virus
Emerging Infectious Disease Agents
Government Advisory & Regulatory Meetings
Blood Products Advisory Committee
Cellular, Tissue and Gene Therapies Advisory Committee
Public Meetings and Workshops
FDA Liaison Meetings - Blood and Blood Components
Cellular Therapies Meetings and Collaborations
Regulatory for Cellular Therapies
HCT/Ps
Biological Products
Investigational Cellular Therapies
International Competent Authorities
Advocacy
Advocacy Agenda
AABB Statements and Comments to FDA
Blood Sustainability
Patient & Donor Safety
Cellular Therapies & Biotherapies
Coverage & Reimbursement
Fact Sheets Created Post Publication of the TRANSFUSION August 2009 Supplement
Middle East Respiratory Syndrome Coronavirus
created July 2013 (PDF)
Human Parvovirus PARV4
created January 2013 (PDF)
Measles (Rubeola)
created October 2011 (PDF)
Miscellaneous Arboviruses
created October 2011 (PDF)
Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and other Polytropic Murine Leukemia Viruses (pMLV)
updated October 2012 (PDF)
Table of Published Studies on XMRV and pMLV Findings in Human Diseases and the General Population
updated September 2012 (PDF)
Yellow Fever Virus and Yellow Fever Vaccine
created March 2011 (PDF)
Fact Sheets Updated after Original Publication (original versions of each fact sheet are available in the
TRANSFUSION August 2009 Supplement
)
Chikungunya Virus
updated February 2014 (previously published in TRANSFUSION) (PDF)
Dengue Viruses
updated February 2014 (previously published in TRANSFUSION) (PDF)
Hepatitis E Virus
updated February 2014 (previously published in TRANSFUSION) (PDF)
Anaplasma phagocytophilum
updated July 2013 (previously published in TRANSFUSION) (PDF)
Babesia
Species
updated July 2013 (previously published in TRANSFUSION) (PDF)
Ehrlichia
Species
updated July 2013 (previously published in TRANSFUSION) (PDF)
Hepatitis A Virus
updated July 2013 (previously published in TRANSFUSION) (PDF)
Human Parvovirus B19
updated January 2013 (previously published in TRANSFUSION) (PDF)
Bartonella
Species
updated February 2012 (previously published in TRANSFUSION) (PDF)
Chronic Wasting Disease (CWD)
updated October 2011 (previously published in TRANSFUSION) (PDF)
Human Prion Diseases (Other than vCJD)
updated October 2011 (previously published in TRANSFUSION as CJD) (PDF)
Variant Creutzfeldt–Jakob Disease (vCJD)
updated October 2011 (previously published in TRANSFUSION) (PDF)
Coxiella burnetii (Q fever)
updated December 2010 (previously published in TRANSFUSION) (PDF)
Japanese Encephalitis Virus Complex
updated December 2010 (previously published in TRANSFUSION) (PDF)
Tick-Borne Encephalitis Virus Complex
updated December 2010 (previously published in TRANSFUSION) (PDF)
Return to Emerging Infectious Disease Agents